Neurogene Inc. (NGNE) shareholders
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Prudential Financial Inc | 2,231,357 | 11.20% | 13G (passive) | Sep 30, 2026 |
| Jennison Associates LLC | 2,229,082 | 11.10% | 13G (passive) | Sep 30, 2026 |
| Samsara BioCapital GP, LLC Joint filing with Samsara BioCapital, L.P. (11.60%), Dr. Srinivas Akkaraju (11.60%) | 1,717,127 | 11.60% | 13G (passive) amendment | Nov 25, 2024 |
| Jeremy C. Green Joint filing with Redmile Group, LLC (9.90%), Redmile Biopharma Investments I, L.P. (5.10%) | 1,572,202 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (9.90%) | 1,557,179 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (9.99%) | 1,498,829 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (9.90%), EcoR1 Capital Fund Qualified, L.P. (8.60%) | 1,442,902 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Eli Casdin Joint filing with Casdin Capital, LLC (8.70%), Casdin Partners Master Fund, L.P. (7.20%) and 1 more | 1,295,361 | 8.70% | 13G (passive) amendment | Dec 31, 2024 |
| Rachel McMinn, Ph.D | 1,273,351 | 9.90% | 13D (active) | Dec 18, 2023 |
| BlackRock, Inc. | 1,011,436 | 6.80% | 13G (passive) amendment | Mar 31, 2025 |
| Felix J. Baker Joint filing with Julian C. Baker (7.00%), Baker Bros. Advisors LP (7.00%) and 1 more | 991,804 | 7.00% | 13G (passive) amendment | Jun 30, 2025 |
| Balyasny Asset Management L.P. Joint filing with Bam Gp LLC (5.18%), Balyasny Asset Management Holdings LP (5.18%) and 2 more | 818,706 | 5.18% | 13G (passive) | Jun 30, 2026 |
| Ortav Yehudai Joint filing with Trails Edge Capital Partners, LP (5.10%), Trails Edge Biotechnology Master Fund, LP (5.10%) | 785,000 | 5.10% | 13G (passive) | Dec 8, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NGNE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 1,717,127 | 8.58% | $54.00M | – | 4.44% |
| Casdin Capital, LLC | 1,545,361 | 7.72% | $48.60M | +125,000 | 2.43% |
| Redmile Group, LLC | 1,412,199 | 7.06% | $44.41M | −47,400 | 2.98% |
| Rtw Investments, LP | 1,362,456 | 6.81% | $42.85M | – | 0.37% |
| EcoR1 Capital, LLC | 1,271,342 | 6.35% | $39.98M | – | 1.94% |
| BlackRock, Inc. | 1,057,983 | 5.29% | $33.27M | +52,913 | 0.00% |
| Baker Bros. Advisors LP | 991,691 | 4.96% | $31.19M | – | 0.16% |
| Balyasny Asset Management L.P. | 818,706 | 4.09% | $25.75M | +100,317 | 0.03% |
| Trails Edge Capital Partners, LP | 714,885 | 3.57% | $22.48M | −67,902 | 3.57% |
| Toronto Dominion Bank | 681,337 | 3.40% | $21.43M | – | 0.02% |
| Vanguard Capital Management LLC | 536,525 | 2.68% | $16.87M | +21,798 | 0.00% |
| Jennison Associates LLC | 518,582 | 2.59% | $16.31M | −9,103 | 0.01% |
| Citadel Advisors LLC | 408,982 | 2.04% | $12.86M | +21,951 | 0.00% |
| Great Point Partners LLC | 352,180 | 1.76% | $11.08M | −147,820 | 2.09% |
| ArrowMark Colorado Holdings LLC | 342,453 | 1.71% | $10.77M | −182,343 | 0.45% |
| FMR LLC | 295,561 | 1.48% | $9.30M | −87,086 | 0.00% |
| Geode Capital Management, LLC | 293,182 | 1.47% | $9.22M | +14,179 | 0.00% |
| State Street Corp | 224,322 | 1.12% | $7.05M | −88,683 | 0.00% |
| Franklin Resources Inc | 204,280 | 1.02% | $6.42M | New | 0.00% |
| Morgan Stanley | 191,724 | 0.96% | $6.03M | −93,515 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 112 | 17M | 86.5% | 22 / 38 | 31 / 4 | 1M | 1M |
| Q1 2026 | 96 | 17M | 84.8% | 19 / 43 | 16 / 15 | 2M | 1M |
| Q4 2025 | 93 | 17M | 82.5% | 14 / 24 | 29 / 7 | 2M | 1M |
| Q3 2025 | 88 | 15M | 76.5% | 16 / 24 | 25 / 10 | 1M | 1M |
| Q2 2025 | 82 | 15M | 76.9% | 9 / 27 | 29 / 12 | 1M | 2M |
| Q1 2025 | 85 | 16M | 82.2% | 15 / 29 | 24 / 17 | 2M | 2M |
| Q4 2024 | 88 | 16M | 80.4% | 28 / 30 | 17 / 25 | 5M | 3M |
| Q3 2024 | 86 | 14M | 69.2% | 23 / 22 | 22 / 2 | 3M | 1M |
| Q2 2024 | 66 | 13M | 66.7% | 22 / 21 | 14 / 16 | 2M | 2M |
| Q1 2024 | 60 | 13M | 65.8% | 32 / 11 | 10 / 7 | 4M | 1M |
| Q4 2023 | 35 | 10M | 48.2% | 35 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
118 funds held NGNE in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NGNE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 397,791 | 1.99% | $12.51M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 296,322 | 1.48% | $9.32M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 218,783 | 1.09% | $7.20M | 0.62% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 177,200 | 0.89% | $5.83M | 0.26% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 126,728 | 0.63% | $3.99M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 124,026 | 0.62% | $4.08M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 105,167 | 0.53% | $3.31M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 90,867 | 0.45% | $2.86M | 0.05% | Jun 30, 2026 |
| iShares Biotechnology ETF | 88,398 | 0.44% | $2.78M | 0.03% | Jun 30, 2026 |
| Meridian Small Cap Growth Fund | 75,859 | 0.38% | $2.39M | 0.87% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 57,993 | 0.29% | $1.64M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 55,794 | 0.28% | $1.58M | 0.00% | May 31, 2026 |
| Select Biotechnology Portfolio | 51,100 | 0.26% | $1.45M | 0.03% | May 31, 2026 |
| iShares Micro-Cap ETF | 37,552 | 0.19% | $1.18M | 0.08% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 27,503 | 0.14% | $904.57K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rachel McMinn | Chief Executive Officer, Director | 1,345,063 | 6.72% | Oct 2, 2026 |
| Christine Mikail Cvijic | President and CFO, Director | 84,040 | 0.42% | Jul 7, 2026 |
| Christina Shafer | Chief Commercial Officer | – | – | May 7, 2026 |
| Julie Jordan | Chief Medical Officer | 12,472 | 0.06% | Mar 30, 2026 |
| Stuart Cobb | Chief Scientific Officer | 30,497 | 0.15% | Mar 17, 2026 |
| Keith Woods | Director | – | – | Jun 16, 2026 |
| Sarah B. Noonberg | Director | – | – | Feb 24, 2026 |
| Rohan Palekar | Director | – | – | Feb 24, 2026 |
| Robert Baffi | Director | – | – | Feb 24, 2026 |
| Cory S. Freedland | Director | – | – | Feb 24, 2026 |
| Robert Keith Woods | Director | – | – | Jun 13, 2025 |
| Srinivas Akkaraju | 10% owner | 1,689,105 | 8.44% | Nov 27, 2024 |
| Samsara BioCapital GP, LLC | 10% owner | 1,668,357 | 8.34% | Nov 27, 2024 |
| Samsara BioCapital, L.P. | 10% owner | – | – | Nov 27, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rachel McMinn Chief Executive Officer, Director | Sep 22, 2026 | Option exercise | +756 | $25.32 | $19.14K | 1,345,063 |
| Christine Mikail Cvijic President and CFO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −4,200 | $36.13 | $151.75K | 84,040 |
| Christine Mikail Cvijic President and CFO, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −600 | $36.02 | $21.61K | 88,240 |
| Christine Mikail Cvijic President and CFO, Director | Jul 2, 2026 | Sale(10b5-1 plan) | −1,530 | $35.23 | $53.90K | 88,840 |
| Christine Mikail Cvijic President and CFO, Director | Jul 2, 2026 | Sale(10b5-1 plan) | −2,531 | $34.58 | $87.52K | 90,370 |
| Christine Mikail Cvijic President and CFO, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −739 | $34.06 | $25.17K | 92,901 |
| Christine Mikail Cvijic President and CFO, Director | May 6, 2026 | Sale(10b5-1 plan) | −4,800 | $30.07 | $144.34K | 98,440 |
| Christine Mikail Cvijic President and CFO, Director | May 6, 2026 | Sale(10b5-1 plan) | −4,800 | $32.44 | $155.71K | 93,640 |
| Rachel McMinn Chief Executive Officer, Director | Mar 26, 2026 | Sale(10b5-1 plan) | −3,352 | $22.07 | $73.98K | 1,344,307 |
| Julie Jordan Chief Medical Officer | Mar 26, 2026 | Sale(10b5-1 plan) | −828 | $21.89 | $18.12K | 12,472 |
| Christine Mikail Cvijic President and CFO | Mar 26, 2026 | Sale(10b5-1 plan) | −2,558 | $21.62 | $55.30K | 103,240 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −148 | $22.08 | $3.27K | 30,497 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −3,991 | $20.41 | $81.46K | 33,303 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −2,658 | $21.34 | $56.72K | 30,645 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2026 | Sale(10b5-1 plan) | −2,387 | $20.42 | $48.74K | 107,456 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2026 | Sale(10b5-1 plan) | −1,395 | $21.25 | $29.64K | 106,061 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2026 | Sale(10b5-1 plan) | −263 | $22.02 | $5.79K | 105,798 |
| Christine Mikail Cvijic President and CFO | Feb 27, 2026 | Sale(10b5-1 plan) | −4,800 | $25.11 | $120.53K | 109,843 |
| Stuart Cobb Chief Scientific Officer | Feb 20, 2026 | Award | +16,500 | – | – | 37,294 |
| Julie Jordan Chief Medical Officer | Feb 20, 2026 | Award | +4,900 | – | – | 13,300 |
| Christine Mikail Cvijic President and CFO | Feb 20, 2026 | Award | +22,000 | – | – | 114,643 |
| Rachel McMinn Chief Executive Officer, Director | Feb 20, 2026 | Award | +25,900 | – | – | 1,347,659 |
| Stuart Cobb Chief Scientific Officer | May 14, 2025 | Sale(10b5-1 plan) | −6,797 | $15.15 | $102.97K | 20,794 |
| Rachel McMinn Chief Executive Officer, Director | Mar 26, 2025 | Award | +23,900 | – | – | 1,274,259 |
| Julie Jordan Chief Medical Officer | Mar 26, 2025 | Award | +8,400 | – | – | 8,400 |
| Christine Mikail Cvijic President and CFO | Mar 26, 2025 | Award | +20,300 | – | – | 92,643 |
| Stuart Cobb Chief Scientific Officer | Mar 26, 2025 | Award | +7,200 | – | – | 27,591 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2025 | Sale(10b5-1 plan) | −4,501 | $16.94 | $76.25K | 72,343 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +20,748 | $24.91 | $516.83K | 1,689,105 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +10,803 | $26.01 | $280.99K | 1,699,908 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +15,219 | $26.73 | $406.80K | 1,715,127 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +2,000 | $27.50 | $55.00K | 1,717,127 |
| Christine Mikail Cvijic President and CFO | Nov 22, 2024 | Buy | +24,000 | $20.48 | $491.52K | 76,844 |
| Rachel McMinn Chief Executive Officer, Director | Nov 22, 2024 | Buy | +47,500 | $20.40 | $969.00K | 1,297,859 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2024 | Award | +20,391 | – | – | 20,391 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2024 | Award | +31,903 | – | – | 52,844 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Oct 5, 2023 | Option exercise | +57,049 | – | – | 155,874 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Oct 5, 2023 | Option exercise | +535,601 | – | – | 1,658,190 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +7,676 | $0.69 | $5.30K | 489,092 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +93,091 | $0.69 | $64.23K | 5,551,815 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +5,041 | $0.69 | $3.48K | 494,133 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +61,134 | $0.69 | $42.18K | 5,612,949 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +366 | $0.68 | $249 | 481,416 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +207,676 | $0.68 | $141.22K | 5,454,290 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +17,124 | $0.68 | $11.64K | 481,050 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +4,434 | $0.68 | $3.02K | 5,458,724 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +358 | $0.67 | $240 | 463,926 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +1,740,581 | $0.63 | $1.10M | 5,242,272 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +143,519 | $0.63 | $90.42K | 463,568 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +4,342 | $0.67 | $2.91K | 5,246,614 |
| Sean Michael Smith Interim CFO, Prin Acct Off | Aug 11, 2023 | Sale | −1,323 | $0.62 | $820 | 21,637 |
| Sean Michael Smith Interim CFO, Prin Acct Off | Aug 10, 2023 | Option exercise | +5,000 | – | – | 22,960 |
| Priti Patel – | Apr 3, 2023 | Sale | −3,769 | $0.69 | $2.60K | 37,313 |
| Priti Patel – | Mar 31, 2023 | Option exercise | +10,000 | – | – | 41,082 |
| Priti Patel Chief Medical Officer | Feb 2, 2023 | Sale | −14,380 | $0.60 | $8.63K | 31,082 |
| Sean Michael Smith Principal Accounting Officer | Feb 2, 2023 | Sale | −3,316 | $0.60 | $1.99K | 15,960 |
| Priti Patel Chief Medical Officer | Feb 1, 2023 | Option exercise | +35,000 | – | – | 45,462 |
| Sean Michael Smith Principal Accounting Officer | Feb 1, 2023 | Option exercise | +12,500 | – | – | 19,276 |
| Sean Michael Smith Principal Accounting Officer | Aug 10, 2022 | Option exercise | +5,000 | – | – | 8,431 |
| Sean Michael Smith Principal Accounting Officer | Aug 10, 2022 | Sale | −1,655 | $0.99 | $1.64K | 6,776 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Neurogene's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,000 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christine Mikail Cvijic Officer | May 6, 2026 | 14,400 | $416.74K | May 6, 2026 | Purchase |
| Stuart Cobb Officer | Mar 13, 2026 | 6,797 | $151.57K | Mar 13, 2026 | Restricted Stock Units |
| Christine Mikail Cvijic Officer | Feb 27, 2026 | 9,600 | $188.93K | Feb 27, 2026 | Purchase |
| Stuart Cobb Officer | May 14, 2025 | 6,797 | $105.42K | May 14, 2025 | Restricted Stock Units |
| Martin Babler Director | Mar 7, 2024 | 2,500 | $98.23K | Mar 7, 2024 | Stock Option Exercise |
| Sean Smith Officer | Mar 4, 2024 | 371 | $13.57K | Mar 4, 2024 | Employee Stock Purchase Plan |
| Todd Simpson Director | Feb 9, 2024 | 2,500 | $77.50K | Feb 9, 2024 | Stock Option Exercise |
| Erin Lavelle Director | Feb 6, 2024 | 2,500 | $76.13K | Feb 6, 2024 | Stock Option Exercise |
See a number that looks wrong?